



Newstar Medical Laboratories - Atlanta

975 Cobb Place Blvd NW, STE 218 Kennesaw, GA 30144

Phone: (678) 505-8016 | Fax:(678) 806-7192

CLIA ID: 11D2145553

Laboratory Director : Chesie Voma

PATIENT

DEMOGRAPHICS

Patient Name: MARY JONES	Account: Desert Kidney Associates Casa Grande Florence	Order Code: 2021-0011992
DOB: 12/22/1951	Provider: Ruchir Patel	Sample Type: Urine
Patient Gender: F	Accession: 21120600024	Collected: 12/02/2021
Patient Phone Number: (520) 868-4812	Report Status:	Received: 2021-12-06T15:34:17.181050
		Reported: 03/28/2022

PRESCRIPTION

LIST

Losartan (Cozaar) , Amlodipine (Norvasc) , Furosemide (Lasix) , Atorvastatin (Lipitor) , Oxycodone (OXY , Percocet , Endocet , Percodan , Percolone , Roxicodone , Tylox) , Vitamin D3 (cholecalciferol-D3) (D3-50) , Triamcinolone (Aristocort) , Zolpidem (Ambien)	C20, Z51.81, Z79.899, I10 Hypertension, N18.2
--	---

INCONSISTENT				INCONSISTENT			
NOT PRESCRIBED		DETECTED		PRESCRIBED		NOT DETECTED	
Class	Test	Cutoff (ng/mL)	Results (ng/mL)	Class	Test	Cutoff (ng/mL)	
STIMULANT	Caffeine	0	> 2500	STATIN	Atorvastatin	0	
	[DDI] The metabolism of Zolpidem can be decreased when combined with Caffeine.						
	[DDI] The metabolism of Zolpidem can be decreased when combined with Caffeine.						

CONTRAINDICATION		NOT TESTED
Drug	Contraindication	
Losartan	[DDI] The metabolism of Atorvastatin can be decreased when combined with Losartan.	
Furosemide	[DDI] The therapeutic efficacy of Furosemide can be decreased when used in combination with Oxymorphone. The risk or severity of renal failure and hypotension can be increased when Furosemide is combined with Losartan. The therapeutic efficacy of Furosemide can be decreased when used in combination with Oxycodone.	
Triamcinolone	[DDI] The metabolism of Oxycodone can be increased when combined with Triamcinolone. The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Furosemide. The metabolism of Zolpidem can be increased when combined with Triamcinolone. The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Atorvastatin. The metabolism of Amlodipine can be increased when combined with Triamcinolone.	
Zolpidem	[DDI] Oxycodone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Oxymorphone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. The metabolism of Zolpidem can be decreased when combined with Losartan.	

CONSISTENT						
PRESCRIBED		DETECTED				
Class	Test	Cutoff (ng/mL)	Results (ng/mL)			
CARDIOVASCULAR	Amlodipine	0	87.01			
	[DDI] Amlodipine may increase the hypotensive activities of Furosemide.					
	[DDI] Amlodipine may increase the hypotensive activities of Furosemide.					
OPIOID	Oxycodone	0	61.73			
	[DDI] The metabolism of Atorvastatin can be decreased when combined with Oxycodone. The risk or severity of adverse effects can be increased when Oxycodone is combined with Oxymorphone.					
	[DDI] The metabolism of Atorvastatin can be decreased when combined with Oxycodone. The risk or severity of adverse effects can be increased when Oxycodone is combined with Oxymorphone.					
OPIOID	Noroxycodone	0	186.03			
	Metabolite of Oxycodone					
OPIOID	Oxymorphone	0	232.47			
	Metabolite of Oxycodone					
	Noroxymorphone	0	64.78			

VALIDITY TESTING & SCREENS		
Specimen Validity	Range	Results
PH	4.50 - 8.00	5.8
Specific Gravity	1.01 - 1.03	1.009
Urine Creatinine (mg/dL)	20.00 - 400.00	27.14



PATIENT

DEMOGRAPHICS

Patient Name: MARY JONES

DOB: 12/22/1951

Patient Gender: F

Patient Phone Number: (520) 868-4812

Account: Desert Kidney Associates Casa Grande Florence

Provider: Ruchir Patel

Accession: 21120600024

Report Status:

Order Code: 2021-0011992

Sample Type: Urine

Collected: 12/02/2021

Received: 2021-12-06T15:34:17.181050

Reported: 03/28/2022

NOT PRESCRIBED						NOT DETECTED					
Test		Cutoff (ng/mL)	Test		Cutoff (ng/mL)	Test		Cutoff (ng/mL)	Test		Cutoff (ng/mL)
Quetiapine			alpha-Hydroxyalprazolam			Dihydrocodeine			Norbuprenorphine		
Ritalinic Acid			Alprazolam			Diltiazem			Nordiazepam		
Sertraline			Amitriptyline			Ethyl Sulfate			Norfentanyl		
Tapentadol			Amphetamine			Glipizide			Norhydrocodone		
Temazepam			Aripiprazole			Glyburide			Norhydromorphone		
Topiramate			Atenolol			Haloperidol			Normeperidine		
Pitavastatin			Atomoxetine			Hydrocodone			Norpropoxyphene		
Pregabalin			Baclofen			Hydromorphone			Nortriptyline		
Propoxyphene			Buprenorphine			Hydroxybupropion			Norverapamil		
Propranolol			Bupropion			Ibuprofen			Protriptyline		
Paroxetine			Buspirone			Imipramine			Pseudoephedrine		
Phentermine			Carbamazepine			Indomethacin			Risperidone		
Pioglitazone			Carbamazepine Epoxide			Irbesartan			Rivaroxaban		
Diphenhydramine			Carboxycyclopogrel			Levetiracetam			Rosuvastatin		
Donepezil			Carisoprodol			Lisinopril			Salicylic Acid		
Doxepin			Celecoxib			Lorazepam			Sitagliptin		
Duloxetine			Chlorpromazine			Lurasidone			Sumatriptan		
Ethyl Glucuronide			Citalopram			Meperidine			THC-COOH		
Fentanyl			Clonazepam			Meprobamate			Tramadol		
Fluoxetine			Clonidine			Metformin			Trazodone		
Gabapentin			Clopidogrel			Methylphenidate			Valsartan		
O-Desmethyltramadol			Clozapine			Metoprolol			Venlafaxine		
O-Desmethylvenlafaxine			Codeine			Mirtazapine			Verapamil		
Olanzapine			Cotinine			Morphine			Warfarin		
Oxazepam			Cyclobenzaprine			Naloxone			Ziprasidone		
Hydrochlorothiazide			Dehydroaripiprazole			Naproxen			Zolmitriptan		
4-Hydroxydiclofenac			Desipramine			N-Desmethylcitalopram					
7-Aminoclonazepam			Diazepam			N-Desmethylclozapine					
9-Hydroxyrisperidone			Diclofenac			N-Desmethylmirtazapine					
Acetaminophen			Digoxin			N-Desmethyllanzapine					

IMPORTANT DISCLAIMER NOTICE : Newstar warrants that all lab analysis provided is conducted professionally in accordance with all applicable standard laboratory practices and that this data reflects Newstar's attempt to generate accurate results for the specific sample(s) submitted to generate this report. Newstar has developed the tests used during the lab analysis and determined their performance characteristics. The tests have not been cleared or approved by the Food and Drug Administration. The results provided are based on information provided by the Customer. Report results are contingent on the accuracy of the prescription list, diagnosis codes, and government databases used to determine drug contraindications and drug interactions. This data reflects Newstar's attempt to generate accurate results based on the information that was provided to Newstar by the Customer and relying on the established government databases available to Newstar for the specific sample(s). Newstar disclaims any and all liability for any errors and is not responsible for any claims or damages related to the reliability of the test results.